サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1489519

mRNAがんワクチンの世界市場：臨床試験と将来の見通し（2024年）

Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024
出版日: | 発行: KuicK Research | ページ情報: 英文 160 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=142.54円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

mRNAがんワクチンの世界市場：臨床試験と将来の見通し（2024年）
出版日: 2024年06月01日
発行: KuicK Research
ページ情報: 英文 160 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

mRNAワクチンがコロナウィルスの管理に利用されたあの慌ただしい時期から、2019年には臨床研究者たちが、がん疾患の治療にmRNAワクチンを使用することを意図して、熱心に取り組んでいます。コロナウイルスを治療するためのmRNAワクチンの勝利に基づいて、多くの研究者は、最先端のmRNAワクチンは、その排他的な作用機序により、がん患者の治療に使用することができると信じていました。そのため、mRNAがんワクチン市場は今後数年でさらに拡大すると予測されます。現在、この分野の市場は米国と中国に研究開発の面で存在しているが、前臨床試験や臨床試験から明らかなように、欧州諸国のような他の地域も新興地域です。

現在までのところ、mRNAがんワクチンは商業的な世界市場には参入しておらず、2つのmRNAワクチン候補であるCMB-305とmRNA 4157のコンジュゲーションが開発の後期段階（第III相）にあることから、今後5～7年のうちに画期的なmRNAがんワクチンが世界市場に参入することが予想され、最初のmRNAがんワクチンが承認されれば、12～18カ月以内に1億米ドルの売上が見込まれます。

これまで、mRNAがんワクチンの世界の分野は、この革新的な治療法の変革の可能性に加え、研究開発の顕著な進展に後押しされ、前衛的な成長を遂げてきました。蓄積された研究により、mRNAがんワクチンはがんを治療する可能性を秘め、より安全で忍容性の高いプロファイルを示すことが明らかになっており、それによって新たな道が開かれています。mRNAがんワクチンは主に固形がんの治療に使用されていますが、mRNAワクチンによる血液がんの治療も近い将来利用されるようになるでしょう。

世界市場におけるmRNAがんワクチンの開発は順調に進んでいますが、長期的な有効性や他の治療法との競合など、多くの困難やアキレス腱を抱えています。一方、臨床試験のパイプラインは充実しており、そのため、mRNAがんワクチンの領域は今後熱狂的な盛り上がりを見せることが予想され、製薬企業にとってはmRNAがんワクチンの領域を前進させるチャンスとなります。

当レポートは、世界のmRNAがんワクチン市場について調査し、市場の概要とともに、薬剤動向、臨床試験動向、地域別動向、および市場に参入する企業の競合情勢などを提供しています。

目次

第1章 次世代がん免疫療法としてのmRNAワクチン

  • mRNAワクチンの概要
  • mRNAワクチンと他のがん治療法との比較
  • mRNAワクチンと他のワクチン

第2章 世界mRNAがんワクチン臨床試験の洞察：企業別、国別、適応症別、相別

  • 研究
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第3章 世界のmRNAがんワクチンの臨床パイプラインの概要

  • 企業別
  • 国別
  • 適応症別
  • 患者セグメント別
  • 相別
  • 優先度別

第4章 世界のmRNAがんワクチン市場概要

  • 現在の市場動向
  • 将来の市場商業化と臨床機会

第5章 世界のmRNAがんワクチン市場の動向、国別

  • 米国
  • 中国
  • オーストラリア
  • 欧州
  • カナダ
  • 英国

第6章 世界のmRNAがんワクチンの臨床情勢、適応症別

  • 乳がん
  • 脳腫瘍
  • 悪性黒色腫
  • 大腸がん
  • 頭頸部がん
  • 肺がん
  • 子宮頸がん
  • 消化器系がん

第7章 世界のmRNAがんワクチン市場の協力、取引、投資

第8章 mRNAがんワクチン開発のための独自の技術と方法論

第9章 競合情勢

  • BioNTech
  • Combined Therapeutics
  • CureVac
  • EpiVax
  • HDT Bio
  • Immorna
  • Immune Design
  • MDimune
  • Moderna Therapeutics
  • NeoCura
  • pHion Therapeutics
  • Providence Therapeutics
  • Regen BioPharma
  • RNAimmune
  • TransCode Therapeutics
図表

List of Figures

  • Figure 3-1: Global - mRNA Cancer Vaccines Clinical Pipeline by Company (Numbers), 2024
  • Figure 3-2: Global - mRNA Cancer Vaccines Clinical Pipeline by Country (Numbers), 2024
  • Figure 3-3: Global - mRNA Cancer Vaccines Clinical Pipeline by Indication (Numbers), 2024
  • Figure 3-4: Global - mRNA Cancer Vaccines Clinical Pipeline by Patient Segment (Numbers), 2024
  • Figure 3-5: Global - mRNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2024
  • Figure 3-6: Global - mRNA Cancer Vaccines Clinical Pipeline by Priority Status (Numbers), 2023
  • Figure 6-1: KEYNOTE-603 Phase I (NCT03313778) Study - Initiation & Completion Year
  • Figure 6-2: Autogene Cevumeran Phase I (NCT03289962) Study - Initiation & Completion Year
  • Figure 6-3: CVGBM Phase I (NCT05938387) Study - Initiation & Completion Year
  • Figure 6-4: Autogene Cevumeran Phase I (NCT03289962) Study - Initiation & Completion Year
  • Figure 6-5: BNT111 Phase I (NCT04526899) Study - Initiation & Completion Year
  • Figure 6-6: mRNA-4157 Phase II (NCT03897881) Study - Initiation & Completion Year
  • Figure 6-7: mRNA-4157 Phase III (NCT05933577) Study - Initiation & Completion Year
  • Figure 6-8: BNT122 Phase II (NCT04486378) Study - Initiation & Completion Year
  • Figure 6-9: BNT113 Phase II (NCT04534205) Study - Initiation & Completion Year
  • Figure 6-10: mRNA-4157 Phase I (NCT03313778) Study - Initiation & Completion Year
  • Figure 6-11: BI1361849 Phase I/II (NCT03164772) Study - Initiation & Completion Year
  • Figure 6-12: V940 Phase III (NCT06077760) Study - Initiation & Completion Year
  • Figure 6-13: Autogene cevumeran Phase I (NCT04161755) Study - Initiation & Completion Year
  • Figure 6-14: Autogene cevumeran Phase II (NCT05968326) Study - Initiation & Completion Year
  • Figure 8-1: BioNTech - uRNA products
  • Figure 8-2: BioNTech - iNeST technology
  • Figure 8-3: CureVac - CureVac Method for Generation of mRNA Therapeutics
  • Figure 8-4: Moderna - mRNA Technology
  • Figure 8-5: NeoCura - NeoCura Ag Platform
  • Figure 8-6: Providence Therapeutic - mRNA Medicines Platform Benefits

List of Tables

  • Table 1-1: mRNA Vaccines v/s Other Cancer Therapeutic Approaches
  • Table 1-2: mRNA-Based Cancer Vaccines vs. Other Cancer Vaccines
  • Table 4-1: Regulatory Designations Granted to Investigational mRNA Cancer Vaccines
  • Table 5-1: Europe - Ongoing Clinical Trials for mRNA Cancer Vaccines
  • Table 5-2: UK - Ongoing Clinical Trials for mRNA Cancer Vaccines
  • Table 6-1: Breast Cancer - Some mRNA Vaccines in Clinical Trials
  • Table 6-2: Brain Cancer - Some mRNA Vaccines in Clinical Trials
  • Table 6-3: Melanoma - Some mRNA Vaccines in Clinical Trials
  • Table 6-4: Colorectal Cancer - Some mRNA Vaccines in Clinical Trials
  • Table 6-5: Head & Neck Cancer mRNA Vaccines in Clinical Trials
  • Table 6-6: Lung Cancer - Some mRNA Vaccines in Clinical Trials
  • Table 6-7: Cervical Cancer - Some mRNA Vaccines in Clinical Trials
  • Table 6-8: Digestive System Cancers - Some mRNA Vaccines in Clinical Trials
目次

Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024 Report Highlights:

  • mRNA Cancer Vaccines In Clinical Trials: > 60 Vaccines
  • Highest Phase Of Clinical Trials: Phase III ( 2 Vaccine)
  • mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication & Phase
  • First Commercial mRNA Vaccine Approval Expected By 2029
  • US & China Dominating mRNA Cancer Vaccines Clinical Trials: > 45 Vaccines
  • mRNA Vaccines For Skin Cancer Dominating Trials: > 10 Vaccines

From that time impetuous when mRNA vaccines were utilized for the management of coronavirus, in 2019, clinical researchers are working insistently with the intention of using mRNA vaccines for the treatment of cancer ailments. Building on the triumph of mRNA vaccine to cure coronavirus, copious researchers believed that cutting edge mRNA vaccines can be used to treat cancer patients owing to its exclusive mode of action. For that reason, it can be forecast that the market for mRNA cancer vaccine is expected to advance further in the imminent years. Currently, the market for this segment exists in the US coupled with China in terms of research and development; however, other regions, like European countries, are also an emerging area as evident from preclinical and clinical studies.

Until now, no mRNA cancer vaccines have entered into the commercial global market, with 2 mRNA vaccines contenders, CMB-305 in conjugation with mRNA 4157, being in the late phase of development (phase III), it can be prophesied that first breakthrough mRNA cancer vaccine will enter into the global market in upcoming 5-7 years and we contemplates that the casement of first mRNA cancer vaccine will result in an overall revenue of US$ 100 Million after its approval within 12-18 months. According to KuicK Research recent study on global mRNA clinical landscape, 3 to 4 mRNA cancer vaccines are likely to commercially enter the market in following decennium. As well as, with cumulative sales clenches plausibility of more than US$ 5 Billion in years to come.

For that reason, several mRNA cancer vaccines preclinical and clinical trials are ongoing in the domain. For instance, The V Foundation for Cancer Research in collaboration with University of Florida are planning to initiate a phase I/II clinical trial in order to examine the safety as well as immunologic activity of RNA lipid Particle (RNA-LP) Vaccines in patients with recurrent pulmonary osteosarcoma. It is an interventional study, which has an estimated study start date in August 2024 and is projected to be complete by October 2026.

Above this, the domain of mRNA cancer vaccine is experiencing trailblazing growth due to increasing research collaboration, and investments. For instance, in June 2024, Moderna has joined hands with Merck by announcing 3 year data for mRNA-4157 (V940) in combination with Keytruda (pembrolizumab) which established sustained improvement in patients suffering from high-risk stage III/IV melanoma following complete resection. Moreover, the University of Texas MD Anderson Cancer Center in addition to CureVac N.V. proclaimed a co-development along with licensing agreement in order develops novel mRNA-based cancer vaccines in April 2024.

Coupled with collaborations, advancement in technological and drug delivery is also another aspect which is influencing global mRNA cancer vaccine growth. For instance, in August 2023, healthcare professionals from Johns Hopkins Medicine have developed a nanoparticle based design which clenches plausibility to enhance mRNA cancer vaccine delivery.

Hitherto, the global sector of mRNA cancer vaccine has acknowledged an avant-garde growth, fueled by the noteworthy progression in research and development, in addition to the transformative potential of this innovative treatment modality. Accumulating studies have revealed that mRNA cancer vaccines clenches potential of treating cancer and exemplifies safer as well as well tolerated profile, thereby, offering novel avenue. Albeit, mRNA cancer vaccines are predominately used to treat solid tumors; nonetheless, treatment of hematological cancer malignancies by mRNA vaccines are likewise to be utilized in imminent years.

There is a favorable prospect in addition to development mRNA cancer vaccine in the global market but with a number of hardships and Achilles heels, like long term effectiveness and competition from other therapies. In the meantime, there exists a robust and cumbersome pipeline of clinical trials; hence, it is expected that the realm of mRNA cancer vaccine clenches enthusiastic forthcoming; representing an opportunity for pharma companies to advance the realm of mRNA cancer vaccine.

Table of Contents

1. mRNA Vaccines as Next Generation Cancer Immunotherapy

  • 1.1 mRNA Vaccines Overview
  • 1.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches
  • 1.3 mRNA Vaccines v/s Other Vaccines

2. Global mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication & Phase

  • 2.1 Research
  • 2.2 Preclinical
  • 2.3 Phase I
  • 2.4 Phase I/II
  • 2.5 Phase II
  • 2.6 Phase II/III
  • 2.7 Phase III

3. Global Cancer mRNA Vaccines Clinical Pipeline Overview

  • 3.1 By Company
  • 3.2 By Country
  • 3.3 By Indication
  • 3.4 By Patient Segment
  • 3.5 By Phase
  • 3.6 By Priority Status

4. Global mRNA Cancer Vaccines Market Overview

  • 4.1 Current Market Trends
  • 4.2 Future Market Commercialization & Clinical Opportunities

5. Global mRNA Cancer Vaccines Market Trends by Country

  • 5.1 US
  • 5.2 China
  • 5.3 Australia
  • 5.4 Europe
  • 5.5 Canada
  • 5.6 UK

6. Global mRNA Cancer Vaccines Clinical Landscape by Indication

  • 6.1 Breast Cancer
  • 6.2 Brain Cancer
  • 6.3 Melanoma
  • 6.4 Colorectal Cancer
  • 6.5 Head & Neck Cancers
  • 6.6 Lung Cancer
  • 6.7 Cervical Cancer
  • 6.8 Digestive System Cancer

7. Global mRNA Cancer Vaccines Market Collaborations, Deals & Investments

8. Proprietary Technologies & Methodologies for mRNA Cancer Vaccine Development

  • 8.1 FixVac - BioNTech
  • 8.2 iNeST - BioNTech
  • 8.3 NanoReady - Samyang Holdings
  • 8.4 CureVac Method - CureVac
  • 8.5 mRNA platform - Moderna
  • 8.6 NeoCura Ag - NeoCura
  • 8.7 OligoPhore(TM) and SemaPhore(TM) - Altamira Therapeutics
  • 8.8 mRNA Medicines Platform & Proprietary LNP Delivery Technology - Providence

Therapeutic

  • 8.9 RNAimmune

9. Competitive Landscape

  • 9.1 BioNTech
  • 9.2 Combined Therapeutics
  • 9.3 CureVac
  • 9.4 EpiVax
  • 9.5 HDT Bio
  • 9.6 Immorna
  • 9.7 Immune Design
  • 9.8 MDimune
  • 9.9 Moderna Therapeutics
  • 9.10 NeoCura
  • 9.11 pHion Therapeutics
  • 9.12 Providence Therapeutics
  • 9.13 Regen BioPharma
  • 9.14 RNAimmune
  • 9.15 TransCode Therapeutics